-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Introduction: Breast cancer ranks first among female malignant tumors.
Triple-Negative Breast Cancer (TNBC) is the subtype of breast cancer with the highest recurrence rate and mortality rate
.
TNBC is ineffective against hormone therapy and targeted therapy.
At present, traditional chemotherapy is the main treatment method, but the effect is not satisfactory
.
Although cancer immunotherapy has entered a period of rapid development, TNBC immunotherapy is difficult: Although early clinical trials of IMpassion 130 have shown that anti-PD-L1 antibody Atezolizumab (Atezolizumab) combined with albumin-bound paclitaxel (Nab-paclitaxel) ) Can significantly reduce the risk of disease-free progression or death in PD-L1+ TNBC patients.
However, the recent clinical trial of IMpassion 131 showed that atilizumab combined with paclitaxel could not benefit TNBC patients
.
The differences in the results of different clinical trials suggest that different chemotherapeutic drugs may lead to different tumor microenvironment characteristics, which in turn affects the therapeutic effect of immune checkpoint inhibitors
.
Systematic analysis of the changes in the tumor microenvironment before and after medication is the key to understanding the current mechanism of immunotherapy and chemotherapy drugs and improving the overall therapeutic effect of TNBC
.
On October 14, 2021, the international journal Cancer Cell published an online research titled "Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple negative breast cancer" from a Chinese scholar in the form of a Research Article.
Thesis
.
Researchers on this subject collected 78 paired samples from 22 TNBC patients (11 received atilizumab combined with paclitaxel chemotherapy, 11 received paclitaxel single-agent chemotherapy) before and after treatment, by integrating single-cell transcription Group sequencing, T cell receptor sequence sequencing, and chromatin access sequencing, constructed a high-resolution transcriptome and epigroup dynamic map of TNBC patients' tumor microenvironment and peripheral blood-derived immune cells (Figure 1)
.
The research system compared the tumor microenvironment and peripheral blood immune characteristics of responders and non-response patients, clarified the dynamic changes of immune cells under different treatment options, and revealed the effect of anti-PD-L1 immunotherapy combined with paclitaxel chemotherapy in TNBC Mechanism of action
.
Figure 1 The project research plan By comparing the differences in the composition of tumors and peripheral blood immune cells of different responders in the combined drug group, the researchers found that the tumor microenvironment of the responding patients was enriched in two groups of T cells with high expression of CXCL13 (CD8-CXCL13 and CD4).
-CXCL13), these two groups of cells simultaneously highly express T cell toxicity and "depletion" related genes
.
In order to further accurately describe the relationship between changes in the composition and ratio of different immune cells and treatment effects, the researchers designed two indexes: "predictive index" and "therapeutic index".
Through the analysis of "predictive index" and "therapeutic index", research The researchers found that higher baseline levels of CD8-CXCL13 and CD4-CXCL13 can predict better immunotherapy response, and the proportion of these two groups of CXCL13+ T cells in response patients increased significantly after the combination therapy (Figure 2)
.
It is worth noting that the researchers found that in contrast to the combination therapy, paclitaxel single-agent chemotherapy can significantly reduce the CXCL13+ T cells in the tumor microenvironment of the responding patient, and lead to the enrichment of immunosuppressive macrophages in the tumor microenvironment
.
Figure 2 The dynamic changes of T cell subpopulations under different treatment regimens.
In addition, the researchers found that the tumor microenvironment of the responding patient was enriched in two groups of pro-inflammatory macrophages with high expression of CXCL9 and CXCL10, and these two groups were pro-inflammatory There is a significant positive correlation between sex macrophages and CXCL13+ T cells (Figure 3)
.
CXCL9 and CXCL10 can participate in T cell recruitment, and the characteristic genes of pro-inflammatory macrophages are regulated by IFNG and TNF signals, indicating that there is a relationship between CXCL13+ T cells with killing function and pro-inflammatory macrophages with high expression of CXCL9 and CXCL10 Positive feedback signal
.
In contrast, CXCL13+ T cells are almost undetectable in the tumor microenvironment of non-responsive patients, but a large number of macrophages that exert immunosuppressive functions are enriched
.
It is worth noting that the researchers found that the peripheral blood mononuclear cells of the responding patients showed pro-inflammatory characteristics, while the peripheral blood mononuclear cells of the non-responsive patients showed anti-inflammatory characteristics, suggesting that the peripheral blood can reflect the tumor microenvironment to a certain extent.
Features
.
Figure 3 Tumor microenvironment of patients with TNBC and characteristics of myeloid cells in peripheral blood Tumor microenvironment is a complex ecosystem, in which innate immune and adaptive immune cells, stromal cells, cancer cells and their interactions constitute a fine regulatory network , To jointly determine the occurrence and development of cancer
.
Although T cells are the focus of current tumor immunity research, other types of immune cells can also affect the effect of immunotherapy through regulation or interaction with T cells
.
By systematically characterizing the proportion and dynamic changes of immune cells, the researchers found that B cells, especially follicular B cells, were significantly enriched in the tumor microenvironment of responding patients, and they increased significantly after immunotherapy
.
Further through correlation analysis and ligand-receptor interaction pair co-expression analysis, the researchers found that follicular B cells and CXCL13+ T cells are significantly positively correlated and interact (Figure 4)
.
In addition, based on the cell composition at the single cell level and the characteristic gene expression of TCGA public data, the researchers found that cDC1 is significantly positively correlated with CXCL13+ T cells, and cDC1 is significantly increased under the action of immunotherapy, suggesting that cDC1 may be involved in the activation of CXCL13+ T cells
.
Figure 4 The dynamic changes of B cells and DC subpopulations and the association with CXCL13+ T cells.
Dr.
Yuanyuan Zhang, the first author of the paper, said that this study revealed the molecular mechanism of TNBC patients' sensitivity and resistance to anti-PD-L1 immunotherapy, and identified The key immune components and their dynamic changes under immune checkpoint inhibitors and paclitaxel chemotherapy regimens clarify the reasons why paclitaxel chemotherapy combined with atilizumab cannot effectively increase the therapeutic effect of TNBC patients
.
The research results of this subject have important guiding significance for the current immunotherapy combined chemotherapy regimen, suggesting that further systematic evaluation of the molecular mechanism of the combined use of different chemotherapeutic drugs and immunotherapeutic drugs is needed to effectively improve the therapeutic effect of the combination regimen on TNBC patients
.
It is reported that this study is the largest single-cell omics study on TNBC tumor-related immune cells in the world so far.
It provides a reliable basis for in-depth understanding of the immune characteristics of TNBC patients and the mechanism of action of immunotherapy combined with chemotherapy regimens, and also for the follow-up Related research work provides extremely valuable data resources
.
The scientific findings of this research provide new ideas for analyzing the dynamic regulation of immune cells in tumors and other diseases, guiding the clinical classification of TNBC patients to achieve precise treatment, and developing new clinical detection and treatment methods
.
Professor Liu Zhihua from Cancer Hospital of Chinese Academy of Medical Sciences, Professor Zhang Zemin from Peking University Biomedical Frontier Innovation Center (BIOPIC), Professor Ma Fei and Professor Xu Binghe from Cancer Hospital of Chinese Academy of Medical Sciences are the co-corresponding authors of the paper
.
Zhang Yuanyuan, postdoctoral fellow at the Peking University-Tsinghua Joint Center for Life Sciences (CLS), Dr.
Hongyan Chen and Dr.
Hongnan Mo from the Cancer Hospital of the Chinese Academy of Medical Sciences, and Dr.
Xueda Hu from Baiao Zhihui are the co-first authors of the paper
.
The research was supported and funded by the Beijing Municipal Science and Technology Commission, the National Natural Science Foundation of China, and the National Key Research and Development Program
.
Reference material: https:// Note: This article aims to introduce the progress of medical research and cannot be used as a reference for treatment options
.
If you need health guidance, please go to a regular hospital
.
Recommendation·Activity Practitioners of Action Knowledge-Seeking Causes of Single-Cell Research and Creation Camp Hot·Article Gene Sequencing [BMJ] Benefits all mankind! The pain of rare disease diagnosis will become history, and whole-genome sequencing is an inevitable trend in medical development! Genetic disease treatment 【Science】The era of RNA drugs has arrived, and the future is boundless! It may soon bring new insights into cancer treatment [AACR sub-Journal] for patients with rarer genetic diseases! Gastric Cancer Atlas brings new treatment strategies! Scientific research [Science] Transplanting skin and nerves from genetically modified pigs can help humans, but the new era of xenotransplantation has not yet arrived.
New crown virus [The Lancet] The world's largest study of 12 million people: New crown vaccine booster against Delta How much protection can the aspect bring to you? Cancer Treatment [Science Sub-Journal] How to treat non-small cell lung cancer more effectively? Scientists at MIT have discovered a way to bring hope to patients! Novel Coronavirus [Nature Hot Discussion] Will the 28 million children in the United States benefit from the FDA's move? What is the role and significance of children's vaccinations against the new crown?